Evidence map›Paper›PMID 38558317›Full record

SynthesisEuropean journal of clinical pharmacology2024

Comparing the effect of fluoxetine, escitalopram, and sertraline, on the level of BDNF and depression in preclinical and clinical studies: a systematic review.

Nastaran Talaee, Shataw Azadvar, Sanaz Khodadadi, Nahal Abbasi, Zahra Najafi Asli-Pashaki, Yasaman Mirabzadeh, Gita Kholghi, Shahin Akhondzadeh, Salar Vaseghi

Abstract readSystematic ReviewComparative Study
PubMed Publisher
In one paragraph

Synthesis in European journal of clinical pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 3 pooled it
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 1 country.

Nastaran Talaee *Department of Psychology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Shataw Azadvar *Department of Power Electronic, Faculty of Electrical Engineering, Sahand University of Technology, Tabriz, Iran.
Sanaz Khodadadi *Student Research Committee, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Nahal Abbasi *Department of Health Psychology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Zahra Najafi Asli-Pashaki *Medical Physics Department, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Yasaman MirabzadehInstitute of Biochemistry and Biophysics (IBB), University of Tehran, Tehran, Iran.
Gita KholghiDepartment of Psychology, Faculty of Human Sciences, Tonekabon Branch, Islamic Azad University, Tonekabon, Iran.
Shahin AkhondzadehPsychiatric Research Center, Department of Psychiatry, Faculty of Medicine, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Salar VaseghiCognitive Neuroscience Lab, Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, 1419815477, Iran. vaseghi@imp.ac.ir.
Islamic Azad University, Science and Research Branch · IRAcademic Center for Education, Culture and Research · IRIran University of Medical Sciences · IRIslamic Azad University Medical Branch of Tehran · IRIslamic Azad University Tonekabon · IRSahand University of Technology · IRTehran University of Medical Sciences · IRUniversity of Tehran · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain-derived neurotrophic factor (BDNF) dysfunction is one of the most important mechanisms underlying depression. It seems that selective serotonin reuptake inhibitors (SSRIs) improve depression via affecting BDNF level. In this systematic review, for the first time, we aimed to review the effect of three SSRIs including fluoxetine, escitalopram, and sertraline, on both depression and BDNF level in preclinical and clinical studies. PubMed electronic database was searched, and 193 articles were included in this study. After reviewing all manuscripts, only one important difference was found: subjects. We found that SSRIs induce different effects in animals vs. humans. Preclinical studies showed many controversial effects, while human studies showed only two effects: improvement of depression, with or without the improvement of BDNF. However, most studies used chronic SSRIs treatment, while acute SSRIs were not effectively used and evaluated. In conclusion, it seems that SSRIs are reliable antidepressants, and the improvement effect of SSRIs on depression is not dependent to BDNF level (at least in human studies).

Indexed as

Brain-Derived Neurotrophic FactorDepressionFluoxetineSelective Serotonin Reuptake InhibitorsSertralineAnimalsAntidepressive AgentsEscitalopramHumansAntidepressive AgentsBDNF protein, humanBrain-Derived Neurotrophic FactorEscitalopramFluoxetineSelective Serotonin Reuptake InhibitorsSertralineBrain-derived neurotrophic factor (BDNF)DepressionFluoxetine, EscitalopramSelective serotonin reuptake inhibitors (SSRIs)Sertraline

Identifiers

PMID38558317
OpenAlexW4393375316

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.